Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin after acute myocardial infarction to reduce cardiac remodeling
2024-511882-13-01Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI), left ventricular systolic dysfunction (LVSD) and heart failure (HF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Change in left ventricular ejection fraction and Change in left atrial volume. Started Nov 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)left ventricular systolic dysfunction (LVSD)heart failure (HF)
Beyond the preview
Go deeper on 2024-511882-13-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511882-13-01.